Actualités et vidéos - EVOTEC SEINH O.N. - Anglais

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces change in Management Board 03.09.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions Hamburg, Germany, 03 September 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its...

Dr Matthias Evers steps down as Chief Business Officer effective 01 October 2024 Distribution of responsibilities across other Management Board functions HAMBURG, GERMANY / ACCESSWIRE / September 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024. Matthias was...

EQS-News: Evotec SE / Key word(s): Half Year Results Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths 14.08.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery – higher share of integrated long-term deals will improve...

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024 Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been accelerated Challenging market environment and high fixed cost base led to weaker profitability. Priority reset towards...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb 13.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec Hamburg, Germany, 13 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT,...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders Performance-based and programme-based payments of in total US$ 75 m to Evotec HAMBURG, GERMANY / ACCESSWIRE / August 13, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progress of the Company's strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb 08.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research Hamburg, Germany, 08 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO)...

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / August 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced progress within the Company's strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a US$ 25 m payment to progress further...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec SE reports first half-year 2024 results on 14 August 2024 07.08.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 07 August 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024. The Company is going to hold a conference call to discuss the...

HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Webcast details Date: Wednesday, 14 August 2024 Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT) To...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec provides guidance update 06.08.2024 / 21:07 CET/CEST The issuer is solely responsible for the content of this announcement. Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France Further strengthened sales...

EQS-Ad-hoc: Evotec SE / Key word(s): Change in Forecast Evotec SE provides guidance update 06-Aug-2024 / 21:04 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc: Evotec SE provides guidance update Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9,...

Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just - Evotec Biologics with mid double-digit revenue growth versus strong comparable basis Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France Further strengthened sales order book in Discovery is basis for a moderate growth acceleration in H2 2024; conversion of orders into revenues taking longer than anticipated Reset towards sustainable profitable...

HAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024. The Company expects Group revenues in the range of € 790 - 820 m (low to mid-single-digit percentage growth vs previously low double-digit percentage growth; 2023: € 781.4 m); R&D expenditures are expected in a range of € 50 - 60 m (low double-digit...

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Pfizer collaborate to advance drug discovery in France 10.07.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases Hamburg, Germany, 10 July 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year...

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases....

EQS-News: Evotec SE / Key word(s): Miscellaneous Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz 08.07.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security Hamburg,...

Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY and SEATTLE, WA / ACCESSWIRE / July 8, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced that its biologics segment, Just - Evotec Biologics, Inc., has expanded...

EQS-News: Evotec SE / Key word(s): Miscellaneous Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program 25.06.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug...

Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program Manufacturing Optimization Program effort enhances U.S. Government's rapid response capabilities for biologics MCMs in response to emergency situations HAMBURGSUND, SWEDEN / ACCESSWIRE / June...